Livforsakringsbolaget Skandia, Omsesidigt Exelixis, Inc. Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $2.1 Billion
- Q2 2025
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Exelixis, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 78,100 shares of EXEL stock, worth $3.44 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
78,100
Previous 111,158
29.74%
Holding current value
$3.44 Million
Previous $4.9 Million
29.74%
% of portfolio
0.16%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
624Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.48 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.26 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$993 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$653 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$520 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $14.2B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...